

| | |
|-------------------------|------------------|
| Reference: | FOI.4614.20 |
| Subject: | Migraine |
| Date of Request: | 26 November 2020 |

Requested:

1. Please provide the number of patients treated (for any condition) in the last 4 months with:
 - Ajoovy (fremanezumab)
 - Aimovig (erenumab)
 - Emgality (galcanezumab)
2. How many of these patients were treated as part of a free or nominal charge scheme with:
 - Ajoovy (fremanezumab)
 - Aimovig (erenumab)
 - Emgality (galcanezumab)
3. How many patients have you treated in the last 4 months for:
 - Any type of migraine
 - Chronic migraine (15+ headache days per month)
 - Episodic migraine (4+ headache days per month)
4. Please provide the number of migraine patients treated in the last 4 months with Botulinum Toxin (i.e. Botox, Dysport, Xeomin).
5. In case you do not treat chronic or episodic migraine, can you please tell us which hospital or trust you refer these patients to?

Response:

1. & 2. Hywel Dda University Health (UHB) confirms that no patients have been treated with the listed medications for the most recent four (4) months.
3. The UHB is unable to provide you with the information requested for question 3, as it is estimated that the cost of answering your request would exceed the “appropriate level” as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004. The “appropriate level” represents the estimated cost of one person spending 18 hours or (2 ½ working days) in determining whether the UHB holds the information, and locating, retrieving and extracting the information.

In order to provide you with all of the information being requested, the UHB would need to undertake a manual search of all neurology outpatient records for the last four (4) months to identify any information that fulfils your request.

Therefore, the UHB is applying an exemption under Section 12 of the Freedom of Information Act 2000 (FOI), which provides an exemption from a public authority’s obligation to comply with a request for information, where the cost of compliance is estimated to exceed the appropriate limit.

4. The UHB provides, within the table below, the number of patients that received Botulinum Toxin, by unit size, as recorded on the pharmacy system for the period 1 August to 30 November 2020.

| Botulinum Toxin unit size | Number of patients |
|----------------------------------|---------------------------|
| Botox 50units | 8 |
| Botox 100units | 12 |
| Botox 200units | 17 |
| Dysport 300units | 20 |
| Dysport 500units | * |

Where the figure in the table has been replaced with an asterisk (*), the UHB is unable to provide you with the exact number of patients due to the low numbers of cases (5 and under), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the Freedom of Information Act 2000. This information is protected by the Data Protection Act 2018/ General Data Protection Regulations 2016 (GDPR), as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles 6 and 9 of the GDPR. This exemption is absolute and therefore there is no requirement to apply the public interest test.

In reaching this decision, the Data Protection Act 2018/General Data Protection Regulations 2016 defines personal data as data which relates to a living individual who can be identified solely from that data or from that data and other information which is in the possession of the data controller.

5. The UHB confirms that patients with chronic migraines are referred to the Botulinum Toxin (Botox) clinics, which are run by the UHB's Pain Service.